APC SPECIFIC MTOP INHIBITION POTENTIATES IMMUNE RESPONSE TO IIV IN ELDERLY RECIPIENTS.

NIH RePORTER · NIH · N43 · $597,598 · view on reporter.nih.gov ↗

Abstract

The contract supports the development of a vaccine adjuvant. The adjuvant development activities will occur within the context of an influenza vaccine.

Key facts

NIH application ID: 10688743
Project number: 75N93022C00006-0-9999-1
Recipient: QRONO, INC
Principal Investigator: SAM ROTHSTEIN
Activity code: N43
Funding institute: NIH
Fiscal year: 2022
Award amount: $597,598
Award type: —
Project period: 2022-01-10 → 2024-01-09